HOCPF:OTC-HOYA Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 111.41

Change

0.00 (0.00)%

Market Cap

USD 41.31B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

N/A

USD 102.35B
ESLOF EssilorLuxottica Société ano..

N/A

USD 97.51B
HOCPY Hoya Corp

N/A

USD 41.31B
RSMDF Resmed Inc DRC

N/A

USD 31.41B
CLPBY Coloplast A

N/A

USD 29.16B
CLPBF Coloplast A/S

N/A

USD 26.54B
TRUMY Terumo Corp ADR

N/A

USD 25.10B
TRUMF Terumo Corporation

N/A

USD 24.91B
SAUHF Straumann Holding AG

N/A

USD 24.13B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 22.04B

ETFs Containing HOCPF

DBJP Xtrackers MSCI Japan Hedg.. 0.00 % 0.47 %

N/A

USD 0.38B
DXJH 0.00 % 0.48 %

N/A

N/A
EWJ iShares MSCI Japan ETF 0.00 % 0.47 %

N/A

USD 16.14B
FLJH Franklin FTSE Japan Hedge.. 0.00 % 0.09 %

N/A

USD 0.06B
FLJP Franklin FTSE Japan ETF 0.00 % 0.09 %

N/A

USD 1.84B
CSJP:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 0.60B
HMJD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

N/A

USD 0.19B
HMJP:LSE HSBC MSCI JAPAN UCITS ETF 0.00 % 0.00 %

N/A

USD 0.19B
IJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

N/A

USD 3.63B
IJPD:LSE iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 0.42B
IJPE:LSE iShares MSCI Japan EUR He.. 0.00 % 0.00 %

N/A

USD 0.74B
IJPN:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

N/A

USD 1.10B
IJPU:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

N/A

USD 1.10B
JPEH:LSE SPDR® MSCI Japan EUR Hdg.. 0.00 % 0.00 %

N/A

USD 0.04B
JPJP:LSE SPDR® MSCI Japan UCITS E.. 0.00 % 0.00 %

N/A

USD 77.76B
JPXG:LSE 0.00 % 0.00 %

N/A

N/A
JPXU:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

N/A

USD 0.01B
JPXX:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

N/A

USD 9.86M
LCJD:LSE Amundi MSCI Japan (DR) UC.. 0.00 % 0.00 %

N/A

USD 636.40B
LCJG:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

USD 0.04B
LCJP:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

USD 642.91B
SJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

N/A

USD 5.61B
IJPH:LSE iShares MSCI Japan GBP He.. 0.00 % 0.00 %

N/A

USD 0.12B
UB02:LSE UBS MSCI Japan UCITS JPY .. 0.00 % 0.00 %

N/A

USD 114.68B
UB0D:LSE UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.10B
UC65:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

N/A

USD 113.22B
XDNG:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

N/A

USD 0.01B
XDNS:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

N/A

USD 55.23B
XDNU:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

N/A

USD 2.03M
XDNY:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

N/A

USD 55.23B
XMJD:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

N/A

USD 2.29B
XMJG:LSE 0.00 % 0.00 %

N/A

N/A
XMJP:LSE Xtrackers MSCI Japan UCIT.. 0.00 % 0.00 %

N/A

USD 2.29B
XMUJ:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

N/A

USD 0.03B
UB0C:LSE 0.00 % 0.00 %

N/A

N/A
CJPU:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

N/A

USD 0.61B
SAJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

N/A

USD 2.13B
SDJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

N/A

USD 2.13B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.97% 63% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.97% 58% F 49% F
Trailing 12 Months  
Capital Gain 2.31% 76% C+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.31% 73% C 62% D
Trailing 5 Years  
Capital Gain 54.31% 80% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.31% 73% C 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.96% 59% D- 59% D-
Dividend Return 11.96% 52% F 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.24% 80% B- 76% C+
Risk Adjusted Return 43.91% 84% B 82% B
Market Capitalization 41.31B 96% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.